The stock of Cempra Inc (NASDAQ:CEMP) is a huge mover today! About 5.82 million shares traded hands or 133.73% up from the average. Cempra Inc (NASDAQ:CEMP) has declined 64.42% since April 6, 2016 and is downtrending. It has underperformed by 66.37% the S&P500.
The move comes after 8 months negative chart setup for the $282.77 million company. It was reported on Nov, 8 by Barchart.com. We have $5.24 PT which if reached, will make NASDAQ:CEMP worth $33.93M less.
Cempra Inc (NASDAQ:CEMP) Ratings Coverage
Out of 12 analysts covering Cempra (NASDAQ:CEMP), 5 rate it a “Buy”, 1 “Sell”, while 6 “Hold”. This means 42% are positive. Cempra has been the topic of 20 analyst reports since July 30, 2015 according to StockzIntelligence Inc. Needham maintained it with “Buy” rating and $15 target price in Monday, November 7 report. As per Wednesday, November 2, the company rating was downgraded by Robert W. Baird. The rating was upgraded by Morgan Stanley on Monday, November 16 to “Overweight”. The stock of Cempra Inc (NASDAQ:CEMP) has “Market Perform” rating given on Wednesday, November 2 by Raymond James. The firm earned “Hold” rating on Thursday, November 3 by Stifel Nicolaus. The stock has “Hold” rating given by Jefferies on Monday, November 7. On Thursday, August 13 the stock rating was initiated by Morgan Stanley with “Equal-Weight”. The rating was initiated by Janney Capital with “Buy” on Friday, December 11. The company was maintained on Monday, October 19 by TH Capital. The stock has “Outperform” rating given by Raymond James on Tuesday, September 13.
According to Zacks Investment Research, “Cempra Holdings, LLC is a pharmaceutical company engaged in developing antibiotics for the treatment of bacterial infectious diseases. It focuses on developing antibiotics for treating respiratory tract, skin and skin structure infections and to target the growing problem of antimicrobial resistance. Cempra Holdings, LLC is headquartered in Chapel Hill, North Carolina.”
Insitutional Activity: The institutional sentiment increased to 2.27 in 2016 Q2. Its up 0.72, from 1.55 in 2016Q1. The ratio increased, as 10 funds sold all Cempra Inc shares owned while 23 reduced positions. 14 funds bought stakes while 61 increased positions. They now own 39.80 million shares or 3.16% more from 38.58 million shares in 2016Q1.
Ladenburg Thalmann Financial Ser Inc holds 0% or 230 shares in its portfolio. Citigroup Inc has 0% invested in the company for 28,992 shares. Paradigm Asset Management Limited Liability Co accumulated 0% or 27,900 shares. Ellington Management Grp Ltd Co has 0.24% invested in the company for 10,300 shares. Alpinvest Prtn Bv reported 67,763 shares or 2.21% of all its holdings. Victory Inc accumulated 0% or 768 shares. William Harris Investors Inc holds 0.62% of its portfolio in Cempra Inc (NASDAQ:CEMP) for 151,045 shares. Artal Grp Inc has 100,000 shares for 0.03% of their US portfolio. State Street Corporation last reported 0% of its portfolio in the stock. Perceptive Advisors Ltd Llc holds 170,000 shares or 0.19% of its portfolio. Keybank Natl Association Oh reported 12,500 shares or 0% of all its holdings. Price T Rowe Associates Md holds 0% or 128,686 shares in its portfolio. Stifel Financial has 0.01% invested in the company for 91,666 shares. Axa has invested 0.03% of its portfolio in Cempra Inc (NASDAQ:CEMP). Columbia Prtnrs L L C Inv Mngmt has invested 0.31% of its portfolio in Cempra Inc (NASDAQ:CEMP).
More important recent Cempra Inc (NASDAQ:CEMP) news were published by: Fool.com which released: “Why Cempra Inc. Got Crushed Again” on November 02, 2016, also Businesswire.com published article titled: “Glancy Prongay & Murray Investigates Claims on Behalf of Cempra, Inc …”, Seekingalpha.com published: “Panel Nod Gives Cempra Little Solace” on November 08, 2016. More interesting news about Cempra Inc (NASDAQ:CEMP) was released by: Fool.com and their article: “Why Cempra Inc Got Crushed Today” with publication date: October 28, 2016.
CEMP Company Profile
Cempra, Inc., incorporated on May 16, 2008, is a clinical-stage pharmaceutical company. The Firm is focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Company’s lead product, solithromycin (CEM-101), is being developed in oral capsules, intravenous (IV), and suspension formulations, for the treatment of community-acquired bacterial pneumonia (CABP), as well as for the treatment of gonorrhea and other indications. The Firm also focuses on developing Taksta, which is an antibiotic known as fusidic acid, and is indicated as an oral treatment of acute bacterial skin and skin structure infections (ABSSSI).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.